GSK revises Covid deal with Vir, pulls out of next-gen work
GSK is taking an axe to another of Hal Barron’s legacy pacts, ending a collaboration with Vir Biotechnology working on new antibodies and vaccines against Covid-19.
The companies aren’t cutting ties entirely; they will remain allied on Xevudy (sotrovimab) in markets where it’s authorized, and an experimental “dual function” Covid antibody dubbed VIR-7832. GSK is also keeping its expanded deal with Vir around therapies for influenza and other respiratory diseases.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,900+ biopharma pros reading Endpoints daily — and it's free.